Phenotypic Transitions the Processes Involved in Regulation of Growth and Proangiogenic Properties of Stem Cells, Cancer Stem Cells and Circulating Tumor Cells
- PMID: 38372877
- PMCID: PMC11087301
- DOI: 10.1007/s12015-024-10691-w
Phenotypic Transitions the Processes Involved in Regulation of Growth and Proangiogenic Properties of Stem Cells, Cancer Stem Cells and Circulating Tumor Cells
Abstract
Epithelial-mesenchymal transition (EMT) is a crucial process with significance in the metastasis of malignant tumors. It is through the acquisition of plasticity that cancer cells become more mobile and gain the ability to metastasize to other tissues. The mesenchymal-epithelial transition (MET) is the return to an epithelial state, which allows for the formation of secondary tumors. Both processes, EMT and MET, are regulated by different pathways and different mediators, which affects the sophistication of the overall tumorigenesis process. Not insignificant are also cancer stem cells and their participation in the angiogenesis, which occur very intensively within tumors. Difficulties in effectively treating cancer are primarily dependent on the potential of cancer cells to rapidly expand and occupy secondarily vital organs. Due to the ability of these cells to spread, the concept of the circulating tumor cell (CTC) has emerged. Interestingly, CTCs exhibit molecular diversity and stem-like and mesenchymal features, even when derived from primary tumor tissue from a single patient. While EMT is necessary for metastasis, MET is required for CTCs to establish a secondary site. A thorough understanding of the processes that govern the balance between EMT and MET in malignancy is crucial.
Keywords: Cancer stem Cells; Circulating Tumor cell (CTC); Epithelial-mesenchymal Transition (EMT); Mesenchymal-epithelial Transition (MET).
© 2024. The Author(s).
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures
Similar articles
-
Expression of Epithelial Mesenchymal Transition and Cancer Stem Cell Markers in Circulating Tumor Cells.Adv Exp Med Biol. 2017;994:205-228. doi: 10.1007/978-3-319-55947-6_11. Adv Exp Med Biol. 2017. PMID: 28560676 Review.
-
Mesenchymal-Epithelial Transition and Circulating Tumor Cells in Small Cell Lung Cancer.Adv Exp Med Biol. 2017;994:229-245. doi: 10.1007/978-3-319-55947-6_12. Adv Exp Med Biol. 2017. PMID: 28560677 Review.
-
Cancer metastasis through the prism of epithelial-to-mesenchymal transition in circulating tumor cells.Mol Oncol. 2017 Jul;11(7):770-780. doi: 10.1002/1878-0261.12081. Epub 2017 Jun 9. Mol Oncol. 2017. PMID: 28544498 Free PMC article. Review.
-
The Significance of Epithelial-to-Mesenchymal Transition for Circulating Tumor Cells.Int J Mol Sci. 2016 Aug 11;17(8):1308. doi: 10.3390/ijms17081308. Int J Mol Sci. 2016. PMID: 27529216 Free PMC article. Review.
-
EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.PLoS One. 2020 Mar 26;15(3):e0229903. doi: 10.1371/journal.pone.0229903. eCollection 2020. PLoS One. 2020. PMID: 32214335 Free PMC article.
Cited by
-
Exosomes as novel tools for renal cell carcinoma therapy, diagnosis, and prognosis.Heliyon. 2024 Jun 13;10(12):e32875. doi: 10.1016/j.heliyon.2024.e32875. eCollection 2024 Jun 30. Heliyon. 2024. PMID: 38948044 Free PMC article. Review.
-
Pathogenetic development, diagnosis and clinical therapeutic approaches for liver metastasis from colorectal cancer (Review).Int J Oncol. 2025 Mar;66(3):22. doi: 10.3892/ijo.2025.5728. Epub 2025 Feb 14. Int J Oncol. 2025. PMID: 39950314 Free PMC article. Review.
-
Liquid Biopsy as a New Tool for Diagnosis and Monitoring in Renal Cell Carcinoma.Cancers (Basel). 2025 Apr 25;17(9):1442. doi: 10.3390/cancers17091442. Cancers (Basel). 2025. PMID: 40361369 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous